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ABSTRACT 
BACKGROUND AND OBJECTIVES: To analyze the scientif-
ic evidence on the changes in plasma levels of interleukins, nitric 
oxide, extracellular matrix metalloproteinases, bradykinins, and 
cortisol in patients with chronic pain. 
CONTENTS: The studies were identified by searching the fol-
lowing electronic databases: Pubmed/Medline, Scopus, LILACS, 
and Web of Science, published from June of 2016 to Decem-
ber of 2016. The selected articles were presented in a flow chart 
based on their identification, selection, eligibility and inclusion 
and exclusion criteria. The content of the articles included in the 
study was analyzed to identify the biomarkers present in patients 
with chronic pain. Thirteen articles that addressed the plasma 
biomarkers levels in humans with chronic pain were selected. 
Most of the articles presented the cytokines levels, followed by 
cortisol. Only one article mentioned the nitric oxide, and none 
mentioned what plasma levels of extracellular matrix metallopro-
teinases and bradykinins were identified.
CONCLUSION: Changes were observed in inflammatory and 
anti-inflammatory cytokine plasma levels, and that cortisol is re-
lated to anxiety and depression symptoms in patients with chron-
ic pain. However, it was not possible to identify the changes in 
plasma levels of nitric oxide, bradykinin, and extracellular matrix 
metalloproteinases due to the absence of scientific evidence.
Keywords: Biomarkers, Chronic pain, Plasma.
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RESUMO
JUSTIFICATIVA E OBJETIVOS: Analisar as evidências cientí-
ficas sobre alterações nos níveis plasmáticos de interleucinas, óxi-
do nítrico, metaloproteinases de matriz extracelular, bradicinina 
e cortisol em pacientes com dor crônica. 
CONTEÚDO: Os estudos foram identificados por meio das 
bases de dados eletrônicas: Pubmed/Medline, Scopus, LILACS 
e Web of Science, publicados no período de junho a dezembro 
de 2016. Os artigos selecionados foram classificados em ficha de 
identificação, seleção dos participantes, elegibilidade, critérios de 
inclusão e exclusão. Os artigos selecionados foram avaliados por 
meio de análise de conteúdo, buscando identificar os biomarca-
dores presentes nos pacientes com dor crônica. Foram seleciona-
dos 13 artigos que abordavam a dosagem plasmática de biomar-
cadores em humanos com dor crônica. A maior parte dos artigos 
apresentou a dose de citocinas, seguidos pelo cortisol. Apenas 
um artigo apresentou a dose de óxido nítrico e nenhum artigo 
identificou a dosagem de níveis plasmáticos de metaloproteinases 
de matriz extracelular e bradicinina. 
CONCLUSÃO: Pôde-se verificar modificações nos níveis plas-
máticos de citocinas inflamatórias e anti-inflamatórias, e que os 
níveis plasmáticos de cortisol estão relacionados com os sintomas 
de ansiedade e depressão nos pacientes com dor crônica. No en-
tanto, não foi possível verificar as alterações nos níveis de plasma 
do óxido nítrico, bradicinina e metaloproteinase de matriz extra-
celular devido à ausência de evidências científicas.
Descritores: Biomarcadores, Dor crônica, Plasma.
INTRODUCTION 
Chronic pain is generally defined as persistent pain lasting lon-
ger than three months. However, other definitions favor the in-
clusion of psychosocial factors and the severity of pain in the 
diagnosis of chronic pain. The severity is graded based on its 
intensity, suffering, and impacts related to pain and functional 
impairment1.
Due to these characteristics, it is considered a complex and 
multi-factorial affliction, which makes it difficult to evaluate and 
justify the need for several techniques, such as questionnaires, 
numeric scales, and non-verbal indices, as well as biochemical 
and biomechanical parameters2,3 that although provide for an 
adequate investigation of the disease, make it difficult for the 
use at a large scale. Therefore, it is necessary to understand the 
biological and psychosocial parameters to facilitate the diagnosis 
of the patient with chronic pain.
Due to the complex features of chronic pain, it remains a major 
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only examined with one-dimensional scales that do not reflect 
the diversity of factors that encompass the care and the expe-
rience of chronic pain. An aspect that could facilitate the con-
trol and treatment of chronic pain could be the use of blood 
biomarkers. However, the relationships between chronic pain 
and the continuous presence of nociceptors or inflammatory 
markers in the plasma of patients with chronic pain are not yet 
understood. In addition, there is a lack of clinical diagnostic re-
quirements regarding the use of physiological and biochemical 
biomarkers4. 
Biomarkers are biochemical molecules that aid in the diagnosis 
and the accompaniment of diseases. In pain, the relationship be-
tween proinflammatory biomarkers and pain had been examined 
in patients with painful inflammation such as a key pathological 
feature of the disease process5. In these cases, high-stress levels 
may compromise the hypothalamic-pituitary-adrenal axis, inter-
fering with cortisol secretion, and alter cytokine expression and 
tumor necrosis factor6,7.
Inflammatory cytokines, as well as nitric oxide (NO), play a 
key role in the pathogenesis of persistent and exacerbated pain 
states8. Some publications present the relation of these biomark-
ers with oncologic pain and neuropathic pain9. However, the 
relationships between biomarkers and chronic musculoskeletal 
pain have not been discussed until now.
Therefore, this scoping review was undertaken to evaluate the 
scientific evidence on the changes in plasma levels of interleu-
kins, NO, matrix metalloproteinases (MMP), bradykinins, and 
cortisol in patients with chronic pain.
CONTENTS
Studies were identified by searching the following electronic da-
tabases: Pubmed/Medline (via National Library of Medicine) 
(1990 - present), Scopus (1990 - 2013), ScienceDirect (1990 
- present) and Web of Science (1990 - present), indicated in the 
period from June 2016 to December 2016. The research ques-
tion was: “Do patients with chronic pain have changes in the plas-
ma levels of cytokines, nitric oxide, bradykinin, MMP, and cortisol? 
 
Definition of terms
For that, we selected articles published in the last 10 years, pub-
lished in English, Portuguese, and Spanish. Keywords were select-
ed by Mesh Terms in order to identify the correct nomenclatures. 
They were: “chronic pain” with the AND search operator “Nitric 
Oxide”, “Hydrocortisone”, “Cytokines” “Bradykinin”, “Matrix 
Metalloproteinases”, with the OR operator between them. In or-
der to restrict the search for the type of analysis, the word plasma 
was used as the free term with the AND search operator.
After this initial selection, the titles and abstracts were read and 
evaluated based on our inclusion and exclusion criteria for rel-
evance. Two reviewers independently reviewed the full texts of 
all potentially relevant articles, and the eligibility of each was 
discussed and resolved. If there had been disagreements between 
two evaluators, a third evaluator was consulted. This review was 
performed in order to understand changes in biomarkers plasma 
levels in patients with chronic pain.
Inclusion and exclusion criteria
Studies included in this scoping review: articles describing the 
plasma levels of biomarkers in patients with chronic musculo-
skeletal pain; observational and experimental studies that pre-
sented plasma levels of biomarkers in this population prior to 
treatment and only full-text article citations with no restrictions 
on language. In addition, the following exclusion criteria were 
used: articles that presented dosages of biomarkers in animals; 
studies that showed biomarker dosages that were collected in 
other sample types that are not human plasma. Furthermore, 
meeting abstracts, unpublished data, review articles, and dupli-
cate articles were excluded from the current study.
The initial search resulted in 193 articles fully assessed in this 
review, 94 articles were from Pubmed, 40 from the Web of Sci-
ence, 58 from SCOPUS and one from LILACS. Of these, 62 
were duplicates. The remaining 131 articles were evaluated by 
their abstracts, verifying whether they corresponded to the in-
clusion criteria. After this stage, 47 articles were included for 
the complete evaluation of the study. At this stage, 34 articles 
were excluded, because (although not observed in the summary 
reading) they did not match the inclusion criteria of this study, 
since they did not present biomarker plasma evaluation, or these 
analyses were performed only after some type of treatment.
Regarding the causes of chronic pain, it is possible to observe 
that four articles referred to patients with fibromyalgia, three ar-
ticles were related to chronic pelvic pain, one article reported 
chronic pain caused by sports, one article referred to burning 
mouth syndrome, and one article mentioned temporomandibu-
lar pain. Other articles indicated participants with chronic pain 
without specifying the cause.
Selected articles were published between 2007 and 2016. There 
were two articles published in each of the following years: 2007, 
2012, 2014, 2015 and 2016 with only one article published each 
year in 2008, 2009 and 2013.
Regarding biomarkers analyses (Table 1), it is possible to observe 
that with a total of thirteen articles, nine studies presented cyto-
kine analyses, one study showed NO analyses and four articles 
described cortisol analyses, all in plasma samples. Among the 
most common cytokines were interleukins 6, 2, and 10 (IL-6, 
IL-2, IL-10), tumor necrosis factor alpha (TNF-α) and interfer-
on gamma (INF-γ). 
In summary, six articles identified an increase in interleukins cor-
related to chronic pain. The biomarker with the highest number 
of alterations was IL-6 with three articles reporting increases in 
patients. One study reported decreased levels of IL-6, IL-4, IL-1, 
IL-2, IL-8, and TNF-α, was also indicated to increase in serum 
levels in the chronic pain group. Anti-inflammatory cytokines, IL-
4, IL-5, and IL-13 are reported to have decreased in these studies.
Finally, one study reported a direct correlation between increased 
NO plasma concentration and disease severity. Moreover, in re-
lation to cortisol, it was observed that despite being related to 
depression and other emotional aspects, such as the response to 
stress, there is no difference in plasma concentrations between 
the patient and control group.
In this scoping review, no study was found evaluated plasma bra-
dykinin and MMP in patients with chronic musculoskeletal pain.
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Table 1. Biomarker analysis of selected articles
Autors Sample Biomarkers Result / comparison
1 Koch et al.8 Chronic pain (94)
Healthy controls (6)
Cytokines (TNF-α, GM-CSF, IL-1β, 
IL-6, IL-8, INF-γ, IL-2, IL-4, IL-5, IL-
10); nitric oxide (NO).
Patients with mild pain x control: increased IL-6
Patient with severe pain x control: significant increase of 








Plasma cortisol; adrenaline; prolac-
tin; growing hormone; dopamine; 
L-dopa; epinephrine, norepineph-
rine, cytokines (IL-1, IL-2, IL-4, IL-6, 
TNF-α, IFN-γ, PGE2).
There was no difference between the groups in the hor-
mones;
IL-1, IL-2, TNF-α, IFN, and PGE2 were significantly higher in 
the chronic pain group.
3 Wingenfeld 
et al.11




Plasma cortisol; salivary cortisol; hor-
mone adrenocorticotrophic (ACTH); 
inhibition of the hypothalamic-pi-
tuitary-adrenal (HPA) axis by dexa-
methasone.
Plasma cortisol: there was no difference between groups, 
but with a significant increase after stress. Fibromyalgia 
group has a higher concentration than the chronic pelvic 
pain and control.
In the others, there was no statistical difference.
4 Anderson 
et al.12
Chronic pelvic pain 
(60)
Healthy controls (30)
Plasma cortisol; ACTH; salivar corti-
sol.
Decrease in ACTH hormonal response, with an average res-
ponse of 30% less to control. 
Regarding cortisol, there was no difference between groups.




Cytokines (IFN-y, IL-5, IL-6, IL-8, IL-
10, MCP-1 e MIP1-α).
The concentrations of most cytokines were lower in stimu-
lated patient samples than in controls. IL-6 was the one with 
the greatest decrease.




Cytokines (IFN-y, IL-2, IL-4, IL-6, IL-
10).
IL-6: Mean increase of 242.8% in the patient group when 
compared to healthy controls. The level of IL-6 correlates 
directly with the severity of pain.
IL-4: Mean increase of 136.4% in the patient group when 
compared to healthy controls.
Anti-inflammatory cytokines: There was a statistically signi-
ficant decrease among the patient group when compared to 
healthy controls.
7 Lundh et 
al.15
Chronic pelvic pain 
(32)
Healthy controls (37)
Testosterone; MIF (factor of inhibition 
of the migration of macrophages); 
cytokines (TNF-α, TNF-β, IL-2, IL-
1β); salivar cortisol. 
MIF: Significantly higher in patients than in control.
Testosterone: Less in patients than in control
TNF-α: significantly higher in patients than in control.





Adrenaline; noradrenaline; ACTH; 
plasma cortisol.
Adrenaline: significantly lower in patients.
Depression levels significantly associated with plasma le-




Fibromyalgia (105) Cytokines (IL-1β, IL-2, IL-4, IL-5, IL-
6, IL-7, IL-10, IL-12, IL-13, IL -17, 
G-CSF, GM-CSF, IFN-y and TNF-α); 
chemokines (CXCL8, CCL2 (MCP1) e 
CCL4 (MIP1β)).
There were no significant correlations between cytokine le-
vels and fatigue, depression or stress; there is a trend of 
significance when we compare levels of cytokines and pain.
After post-hoc analysis, there was a marked reduction of 
IL-4, IL-5, and IL-13 cytokines.







Cytokines (MCP-1, MIP-1α, MIP-
-1β, RANTES, ENA-78, FGF basic, 
G-CSF, GM-CSF, IFN-γ, IL-1α, IL-1β, 
IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-8, IL-
10, IL-17, TNF-α, Thrombopoietin, 
VEGF endothelial growth factor); 
RNA expression.
RNA expression: deregulation of miRNA in VBD affects rele-
vant estrogen pathways, whereas, in generalized pain, it is 
related to muscle, nerve cells, and glial cells.
IL-8 and IL-1ra were statistically significant between the 
groups, being higher in the patient group.
Women with VBD and VBD + IBS have increased expression 
of proinflammatory cytokines.
11 Nenke et 
al.19
Chronic pain (26) Salivar cortisol; plasma cortisol. Plasma cortisol: significant reduction in opioid users when 
compared to control, especially at 60 and 120 min.
There was no difference in salivary cortisol.





Cytokines (IL-1, IL-6, IL-8, and GM-
-CSF).
IL-6: significantly higher in patients than in controls.
IL-1, IL-8, and GM-CSF: no difference between the two 
groups.
A multivariate analysis showed a tendency for patients to 
have higher GM-CSF plasma levels than controls.





Cytokines (IL-1β, IL-6, IL-10, and 
TNF-α); 
C-Reactive protein
Patients with major changes had higher scores on pain and 
sleep scores.
The patient group had statistically higher levels of cytokines 
than the control group.
Cytokines had a significant positive relationship with the 
Pittsburgh Sleep Quality Index (PSQI).
IL-10 and TNF-α were associated with the sleepiness scale.
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DISCUSSION 
The present scoping review sought to understand the changes in 
plasma levels of biomarkers cytokines, nitric oxide, bradykinin, 
MMP, and cortisol presented in patients with chronic pain. In 
this review, thirteen articles were found to address these ques-
tions. A greater number of articles with cytokines were identi-
fied, followed by cortisol, only one article regarding NO and 
none for the other biomarkers.
Among the articles which included cytokines, it was possible 
to observe that cytokines were the most evaluated biomarker, 
mainly IL-6, IL-2, and IL-10. However, the one that had the 
strongest relationship to chronic pain was IL-66. Interleukin-6 
is related to both the innate and adaptive immune response. It 
arises in response to microorganisms, but also to stimulation by 
other cytokines such as IL-1 and TNF-α. It is also considered 
the main myosin produced by active skeletal muscles and has 
an acute pro-inflammatory effect, but its presence stimulates the 
increase of other interleukins, such as IL-10, which presents a 
chronic anti-inflammatory effect22. In studies by Koch et al.8 
and Malhotra et al.14, a direct relationship was found between 
the concentration of pro-inflammatory interleukins, mainly 
IL-6, and the severity of chronic pain. Pro-inflammatory cyto-
kine concentrations in this review were related to the presence 
of chronic pain, as six articles have shown that these cytokine 
concentrations were higher in patients with chronic pain than 
in healthy controls13. These studies presented different chronic 
pain charts, so this finding may be related to chronic muscu-
loskeletal pain of different origins. Another relationship found 
in the cytokine and chronic pain ratio was the decrease of an-
ti-inflammatory cytokines in patients with chronic pain when 
compared to controls13,14,17,19. This information may facilitate the 
modification of pain perception, since IL-10, for example, plays 
an important role as a pain perception blocker23.
Concerning NO, only one article was found to evaluate plasma 
dosage. A study by Koch et al.8 showed that serum NO levels 
increase in patients with chronic pain at all severity levels when 
compared to healthy controls. However, although these authors 
also find modifications in the dosages of cytokines, there are 
no references as to the correlation between these variables. It is 
known that NO plays an important role in the synthesis of cyto-
kines and inhibitory factors involved in inflammation24.
Regarding plasma cortisol levels, five studies with this type of 
analysis were found. Among them, only Vaisberg et al.10 eval-
uated plasma cortisol and cytokine levels for chronic pain in 
athletes, but it did not show a relationship between the two bio-
markers. In Vaisberg et al.10, no significant changes were found 
between the groups with chronic pain or chronic pain in serum 
cortisol levels. Additionally, no studies showed a relationship be-
tween cytokines and cortisol. Cytokines can aid in the activation 
of the neuroendocrine axis, increasing the cortisol secretion, and 
a modification in this system, due to the cytokines, the increase 
could explain a chronic release and increase in plasma cortisol7.
Among the five articles that measured plasma cortisol, three pre-
sented significant changes. Wingenfeld et al.11 showed higher con-
centrations of plasma cortisol in the fibromyalgia group than in 
the other groups, which is related to a difficulty in responding 
to stress. Koike et al.8 reported a direct relationship between de-
pressive symptoms and serum cortisol rates. Nenke et al.19 showed 
that patients on opioids treatment had reduced cortisol rates. In 
this view, it seems that patients experiencing chronic pain with 
emotional changes may present changes in plasma cortisol levels.
Taken together, our findings provide evidence that chronic 
musculoskeletal pain can increase pro-inflammatory cytokines, 
mainly IL-6 and NO in serum, as well as decrease IL-10. Corti-
sol seems to be related to the presence of anxiety and depression 
symptoms, which may make it difficult for these patients to cope 
in the face of chronic pain25. Another important aspect is the 
type of chronic pain evaluated. The most cited were not fibromy-
algia and chronic pelvic pain but unspecified chronic pain. This 
aspect identifies many possible factors that develop chronic pain, 
which, after being established, becomes a health problem itself, 
with its own particularities26.
No study was found in the literature to have measured plasma 
MMP or bradykinin content in patients with chronic musculo-
skeletal pain. This may be related to the fact that MMP and bra-
dykinins influence the local inflammatory process when patients 
present tissue injury, but this not always happens in patients with 
chronic pain27. However, it would be important to understand 
the systemic impact of the presence of these biomarkers and their 
impact on chronic pain processes when acute tissue injury ceases.
In this review, it was found that most of the articles deal with 
a cross-sectional observational study, which is justified by the 
guiding question used since this study sought to identify the 
modifications in the biomarkers in patients with chronic pain. 
However, despite being observational studies, they presented a 
high level of evidence, which makes it possible to use them as 
scientific evidence for these biomarkers modifications.
Because of the guiding question, this study did not include ran-
domized clinical trials that could better explain the relationships 
between these biomarkers as well as factors that aggravate or 
ameliorate clinical symptoms and possibly modify biomarker 
dosages. Further studies are required to understand the relation-
ship between biomarkers and other problems associated with 
chronic pain, such as psycho-social aspects.
CONCLUSION
This scoping review can conclude that there are changes in in-
flammatory and anti-inflammatory cytokine plasma levels of 
patients with chronic pain, and that cortisol is related to anxi-
ety and depression symptoms. Regarding NO, bradykinin, and 
MMP, it was not possible to establish this relationship due to the 
absence of studies.
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